BusinessNovan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206By Nasdaq OMXJan 25, 2018, 2:01 PM UTC
BusinessNovan Acquires IP Rights to Treat Viral Malignancies with Nitric OxideBy Nasdaq OMXOct 18, 2017, 11:05 AM UTC
BusinessNovan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual MeetingBy Nasdaq OMXMar 2, 2017, 2:05 PM UTC
BusinessNovan Announces Presentation of Anti-Viral Data at International Papillomavirus ConferenceBy Nasdaq OMXMar 1, 2017, 2:05 PM UTC
BusinessNovan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206By Nasdaq OMXNov 29, 2016, 11:05 AM UTC
